We herein report the first case of remarkable hypertriglyceridemia induced by aliskiren. A 42-year-old man with chronic kidney disease who had been taking antihypertensive medication for approximately 10 years was treated with aliskiren at a dose of 150 mg/day due to uncontrolled hypertension. Six weeks later, although the patient's blood pressure decreased, a laboratory examination revealed remarkable hypertriglyceridemia and an elevated creatinine level. We suspected the occurrence of an adverse event of aliskiren, and the medication was discontinued. Thereafter, the hypertriglyceridemia and elevated creatinine level spontaneously improved. Transient eosinophilia and a strong-positive response of drug lymphocyte stimulation test (DLST) to aliskiren occurred during the patient's clinical course, and we determined the remarkable hypertriglyceridemia to be an adverse event of aliskiren.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2169/internalmedicine.51.8567 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Wet-Cupping's Impact on Pancreatitis Induced by Hypertriglyceridemia: A case study and brief literature review.
Sultan Qaboos Univ Med J
November 2024
Internal Medicine Residency Training Program, Oman Medical Specialty Board, Muscat, Oman.
Article Synopsis
- Familial hypertriglyceridemia is a genetic disorder that causes high levels of triglycerides in the blood, which can lead to acute and chronic pancreatitis.
- A 34-year-old male patient in Muscat, Oman, diagnosed with this condition experienced a significant reduction in triglycerides and a decrease in hospital admissions for pancreatitis after starting cupping therapy.
- This case report suggests that cupping therapy may help manage familial hypertriglyceridemia and lower the risk of pancreatitis.
Etiology, Pathophysiology, and Treatment Strategies in the Prevention and Management of Metabolic Syndrome.
Arch Intern Med Res
October 2024
Department of Translational Research, Western University of Health Sciences, Pomona, California, USA.
Article Synopsis
- Metabolic Syndrome (MetS) is a serious cluster of metabolic issues that increase the risk for chronic diseases like hypertension, type 2 diabetes, and cardiovascular diseases, affecting about 25% of the global population, especially in developed countries.
- It is characterized by central obesity, high blood pressure, insulin resistance, and other biochemical changes that link it to serious health problems like diabetes and cardiovascular diseases.
- Despite ongoing debates about its exact components and relationships, there are promising treatment options available, including drug therapies and surgical interventions, highlighting the need for further research due to its significant impact on public health.
A Case Report of Therapeutic Plasma Exchange in Hypertriglyceridemia-Induced Pancreatitis.
Indian J Hematol Blood Transfus
October 2024
Department of Immunohematology & Blood Transfusion, Bharati Vidyapeeth Deemed University Medical College, Hospital & Research Centre, Pune, Maharashtra India.
To support the evidence of plasma exchange's ability to rapidly lower serum TG levels and provide upcoming research opportunities for evaluating the long-term effects of this treatment, we present the case of a 35-year-old female who was admitted for Hypertriglyceridemia-induced Pancreatitis (HTGP). She underwent Therapeutic Plasma Exchange (TPE) using Spectra Optia Apheresis System on an emergency basis. The patient had a remarkable reduction of serum Triglycerides (TG) from 3953 to 291 mg/dl, which was life saving.
View Article and Find Full Text PDFSalvage treatment of ruxolitinib for refractory adenovirus-associated hemophagocytic syndrome post-haploidentical allogeneic stem cell transplantation: a case report.
Transl Pediatr
June 2024
Department of Hematology and Oncology, Children's Hospital of Nanjing Medical University, Nanjing, China.
Background: Hemophagocytic lymphohistiocytosis (HLH) is a rare complication following hematopoietic stem cell transplantation (HSCT). Currently, there is a lack of consensus recommendations for the treatment of post-transplant HLH. This case report emphasizes the successful utilization of ruxolitinib as a salvage therapy for HLH post-HSCT.
View Article and Find Full Text PDFClinical Characteristics of Children with THRA Mutations: Variable Phenotype and Good Response to Recombinant Human Growth Hormone Therapy.
Horm Res Paediatr
May 2024
Unidade de Endocrinologia Genética (LIM 25), Hospital Das Clínicas da Faculdade de Medicina, Universidade de São Paulo (USP), São Paulo, Brazil.
Introduction: Mutations in the thyroid hormone receptor alpha (THRA) gene are a rare cause of thyroid hormone resistance, which leads to a pleomorphic phenotypic spectrum. Hormonal profiles are variable and subtle, making laboratory diagnoses challenging. Genetic evaluation can be a helpful tool in diagnosing these cases.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!